Epizootiological investigation of equine herpesvirus type 1 infection among Japanese racehorses before and after the replacement of an inactivated vaccine with a modified live vaccine.
Abstract: Equine herpesvirus type 1 (EHV-1) infection is a major cause of pyrexias in winter among Japanese racehorses. In 2014-2015, the Japan Racing Association (JRA) changed the EHV-1 vaccine from an inactivated vaccine to a live vaccine (both produced by Nisseiken). To evaluate the effect of changing the vaccines, the capacities of these vaccines to induce virus-neutralizing (VN) antibodies were compared, and an epizootiological investigation of EHV-1 was performed at the JRA Ritto Training Center during epizootic periods from 2010-2011 to 2016-2017. Results: Three-year-old horses that received the first dose of live vaccine showed higher geometric mean (GM) VN titers (205 and 220) than those that received inactivated vaccine (83, P < 0.05). The response rates after vaccination with the live vaccine (76 and 90%) were higher than that after vaccination with inactivated vaccine (42%, P < 0.05). Four-year-old horses from 2015 to 2017 that had received the live vaccine in the previous epizootic periods had higher GM titers (205 to 246) than those from 2011 to 2014, which had received the inactivated vaccine (139 to 164, P < 0.05). The estimated numbers of horses infected with EHV-1 or EHV-4, or both, in 2011-2012 (29 [95%CI: 21-37]) and 2013-2014 (37 [95%CI: 27-47]) were higher than those in the other periods (7 [95%CI: 2-12] to 16 [95%CI: 9-23]). Likewise, the seroconversion rates to EHV-1 in horses that stayed at the training center in 2011-2012 (66.0%) and 2013-2014 (52.0%) were higher than those in the other periods (12.0 to 28.6%). Conclusions: The live EHV-1 vaccine is highly immunogenic and provides greater VN antibody responses than the inactivated vaccine. Unlike the period when the policy was to use inactivated vaccine, there was no detectable epizootic EHV-1 infection at the training center during three consecutive periods after the introduction of the live vaccine. These results suggest that the replacement of inactivated vaccine with live vaccine, together with the achievement of high vaccination coverage, reinforced the herd effect, and contributed to better control of EHV-1 epizootics in the training center.
Publication Date: 2019-08-06 PubMed ID: 31387602PubMed Central: PMC6683523DOI: 10.1186/s12917-019-2036-0Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
- Journal Article
Summary
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
This study explored the effectiveness of a modified live vaccine compared to an inactivated one in curbing the infection of equine herpesvirus type 1 (EHV-1) among Japanese racehorses, noting that the live vaccine showed stronger results in inducing virus-neutralizing antibodies and controlling EHV-1 outbreaks at the training center.
Vaccine Comparison
- The researchers investigated the potency of two vaccines, a previously used inactivated vaccine and a currently utilized live vaccine, both produced by xNisseiken, targeting EHV-1 among Japanese racehorses.
- They set out to compare the ability of these vaccines to stimulate the production of virus-neutralizing (VN) antibodies, that is, antibodies that can block the effects of viruses, thereby preventing them from causing an infection.
Virus-neutralizing Antibodies
- The study found that three-year-old horses that had received the first dose of the live vaccine exhibited higher geometric mean (GM) VN titers or concentration of antibodies (205 and 220) in comparison to those vaccinated with the inactivated vaccine (83).
- Additionally, the response rates after vaccination using the live vaccine (76 and 90%) were significantly higher than that with the inactivated vaccine (42%).
- Similarly, four-year-old horses from 2015-2017 who had received the live vaccine in previous epizootic periods displayed higher GM titers (205 to 246) than those from 2011-2014, which had received the inactivated vaccine (139 to 164).
EHV-1 Infection Rates
- The study also made an estimated count of horses infected with either EHV-1, EHV-4, or both, during the years 2011-2012 and 2013-2014, which was higher than during other periods.
- Consequently, the seroconversion rates to EHV-1, or the development of detectable specific antibodies to the virus in the blood serum as a result of infection or immunization, were higher during these two periods (66.0% and 52.0%) compared to other periods (12.0 to 28.6%).
Conclusions
- The results showed that the live EHV-1 vaccine was more immunogenic than the inactivated vaccine, leading to better VN antibody responses.
- Furthermore, unlike the period during which the policy was to utilize the inactivated vaccine, there were no detectable EHV-1 outbreaks at the training center during three consecutive periods following the implementation of the live vaccine.
- These findings suggest that the switch from inactivated to live vaccines, along with high vaccination coverage, amplified the herd effect (resistance to the spread of a contagious disease within a population if a sufficiently high proportion of individuals are immune), thereby contributing to better control of EHV-1 outbreaks in the training center.
Cite This Article
APA
Bannai H, Tsujimura K, Nemoto M, Ohta M, Yamanaka T, Kokado H, Matsumura T.
(2019).
Epizootiological investigation of equine herpesvirus type 1 infection among Japanese racehorses before and after the replacement of an inactivated vaccine with a modified live vaccine.
BMC Vet Res, 15(1), 280.
https://doi.org/10.1186/s12917-019-2036-0 Publication
Researcher Affiliations
- Equine Research Institute, Japan Racing Association, 1400-4 Shiba, Shimotsuke, Tochigi, 329-0412, Japan. bannai@equinst.go.jp.
- Equine Research Institute, Japan Racing Association, 1400-4 Shiba, Shimotsuke, Tochigi, 329-0412, Japan.
- Equine Research Institute, Japan Racing Association, 1400-4 Shiba, Shimotsuke, Tochigi, 329-0412, Japan.
- Equine Research Institute, Japan Racing Association, 1400-4 Shiba, Shimotsuke, Tochigi, 329-0412, Japan.
- Equine Research Institute, Japan Racing Association, 1400-4 Shiba, Shimotsuke, Tochigi, 329-0412, Japan.
- Equine Research Institute, Japan Racing Association, 1400-4 Shiba, Shimotsuke, Tochigi, 329-0412, Japan.
- Equine Research Institute, Japan Racing Association, 1400-4 Shiba, Shimotsuke, Tochigi, 329-0412, Japan.
MeSH Terms
- Animals
- Antibodies, Viral / blood
- Herpesvirus 1, Equid
- Herpesvirus 4, Equid
- Horse Diseases / epidemiology
- Horse Diseases / prevention & control
- Horse Diseases / virology
- Horses
- Japan / epidemiology
- Seasons
- Serologic Tests
- Vaccines, Inactivated
- Viral Vaccines / immunology
Conflict of Interest Statement
The authors declare that they have no competing interests.
References
This article includes 13 references
- Crabb BS, Studdert MJ. Equine herpesviruses 4 (equine rhinopneumonitis virus) and 1 (equine abortion virus).. Adv Virus Res 1995;45:153-90.
- Sugiura T, Matsumura T, Fukunaga Y, Hirasawa K. Sero-epizootiological study of racehorses with pyrexia in the training centers of the Japan Racing Association.. Nihon Juigaku Zasshi 1987 Dec;49(6):1087-96.
- Matsumura T, Sugiura T, Imagawa H, Fukunaga Y, Kamada M. Epizootiological aspects of type 1 and type 4 equine herpesvirus infections among horse populations.. J Vet Med Sci 1992 Apr;54(2):207-11.
- Bannai H, Mae N, Ode H, Nemoto M, Tsujimura K, Yamanaka T, Kondo T, Matsumura T. Successful control of winter pyrexias caused by equine herpesvirus type 1 in Japanese training centers by achieving high vaccination coverage.. Clin Vaccine Immunol 2014 Aug;21(8):1070-6.
- TSUJIMURA K, SHIOSE T, YAMANAKA T, NEMOTO M, KONDO T, MATSUMURA T. Equine herpesvirus type 1 mutant defective in glycoprotein E gene as candidate vaccine strain.. J Vet Med Sci 2009 Nov;71(11):1439-48.
- Bannai H, Nemoto M, Tsujimura K, Yamanaka T, Kokado H, Kondo T, Matsumura T. Comparison of protective efficacies between intranasal and intramuscular vaccination of horses with a modified live equine herpesvirus type-1 vaccine.. Vet Microbiol 2018 Aug;222:18-24.
- Goehring LS, Wagner B, Bigbie R, Hussey SB, Rao S, Morley PS, Lunn DP. Control of EHV-1 viremia and nasal shedding by commercial vaccines.. Vaccine 2010 Jul 19;28(32):5203-11.
- Goodman LB, Wagner B, Flaminio MJ, Sussman KH, Metzger SM, Holland R, Osterrieder N. Comparison of the efficacy of inactivated combination and modified-live virus vaccines against challenge infection with neuropathogenic equine herpesvirus type 1 (EHV-1).. Vaccine 2006 Apr 24;24(17):3636-45.
- Yasunaga S, Maeda K, Matsumura T, Kai K, Iwata H, Inoue T. Diagnosis and sero-epizootiology of equine herpesvirus type 1 and type 4 infections in Japan using a type-specific ELISA.. J Vet Med Sci 1998 Oct;60(10):1133-7.
- Andoh K, Takasugi M, Mahmoud HY, Hattori S, Terada Y, Noguchi K, Shimoda H, Bannai H, Tsujimura K, Matsumura T, Kondo T, Maeda K. Identification of a major immunogenic region of equine herpesvirus-1 glycoprotein E and its application to enzyme-linked immunosorbent assay.. Vet Microbiol 2013 May 31;164(1-2):18-26.
- Bannai H, Nemoto M, Tsujimura K, Yamanaka T, Maeda K, Kondo T. Improvement of an enzyme-linked immunosorbent assay for equine herpesvirus type 4 by using a synthetic-peptide 24-mer repeat sequence of glycoprotein G as an antigen.. J Vet Med Sci 2016 Feb;78(2):309-11.
- Bannai H, Nemoto M, Tsujimura K, Yamanaka T, Kondo T, Matsumura T. Development of a focus-reduction neutralizing test for detecting equine herpesvirus type-1-neutralizing antibodies.. J Vet Med Sci 2013;75(9):1209-12.
- Bannai H, Nemoto M, Tsujimura K, Yamanaka T, Kondo T, Matsumura T. Improving a Complement-fixation Test for Equine Herpesvirus Type-1 by Pretreating Sera with Potassium Periodate to Reduce Non-specific Hemolysis.. J Equine Sci 2013;24(4):71-4.
Citations
This article has been cited 2 times.- El Brini Z, Fassi Fihri O, Paillot R, Lotfi C, Amraoui F, El Ouadi H, Dehhaoui M, Colitti B, Alyakine H, Piro M. Seroprevalence of Equine Herpesvirus 1 (EHV-1) and Equine Herpesvirus 4 (EHV-4) in the Northern Moroccan Horse Populations.. Animals (Basel) 2021 Sep 29;11(10).
- Bannai H, Kambayashi Y, Tsujimura K, Nagashima T, Takebe N, Tominari M, Nemoto M, Ohta M. Persistence of virus-neutralizing antibodies in horses inoculated with two doses of a live equine herpesvirus type 1 vaccine with different vaccination intervals.. J Equine Sci 2021;32(3):99-102.
Use Nutrition Calculator
Check if your horse's diet meets their nutrition requirements with our easy-to-use tool Check your horse's diet with our easy-to-use tool
Talk to a Nutritionist
Discuss your horse's feeding plan with our experts over a free phone consultation Discuss your horse's diet over a phone consultation
Submit Diet Evaluation
Get a customized feeding plan for your horse formulated by our equine nutritionists Get a custom feeding plan formulated by our nutritionists
